Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 96 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lisdexamfetamine Clear all
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

NCT01131559
View directory record Official record
Conditions
Bipolar, Depression
Interventions
Lisdexamfetamine, Placebo control
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

NCT01017263
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Glucose Intolerance, Obesity
Interventions
Lis-dexamphetamine
Drug
Lead sponsor
Duke University
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 1, 2026, 9:46 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

NCT06847399
View directory record Official record
Conditions
Obesity and Overweight, Binge Eating Disorder
Interventions
Tirzepatide, Lisdexamfetamine Dimesylate, Guided self-help cognitive behavioral therapy, Placebo (oral), Placebo (injection)
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

NCT02466386
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
50
States / cities
Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Reinforcing Mechanisms of Smoking in Adult ADHD

NCT00573859
View directory record Official record
Conditions
ADHD
Interventions
ADHD medication, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00697515
View directory record Official record
Conditions
ADHD
Interventions
LDX, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Little Rock, Arkansas • Irvine, California • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552915
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
79
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Attention & Memory Impairments in Menopausal Women

NCT01324024
View directory record Official record
Conditions
Symptomatic Menopause, Cognitive Impairments
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

NCT02675400
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
Vyvanse, Behavioral Parent Training, Methylphenidate
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT02009163
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Lisdexamfetamine dimesylate, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Fort Myers, Florida • Lauderhill, Florida • Leesburg, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis

NCT01615887
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
lisdexamfetamine sulfate, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

NCT01399827
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

NCT01235338
View directory record Official record
Conditions
Healthy
Interventions
LDX + Venlafaxine XR, Venlafaxine XR + LDX
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IMProving Executive Function Study

NCT03187353
View directory record Official record
Conditions
Cognitive Impairment, RRSO
Interventions
Lisdexamfetamine, Placebo oral capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
35 Years to 58 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Effects of LDX on Functioning of College Students With ADHD

NCT01342445
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
lisdexamfetamine dimesylate, Placebo
Drug
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 28 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethlehem, Pennsylvania • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Early Phase 1 Interventional

Mindfulness-Based ADHD Treatment for Children: a Feasibility Study

NCT04737512
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mindfulness-Based ADHD Treatment for Children, Goal-Standard Medication (Treatment as Usual)
Behavioral · Biological
Lead sponsor
Yale University
Other
Eligibility
7 Years to 13 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552902
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
81
States / cities
Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Terminated Phase 3 Interventional Results available

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

NCT01738698
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment

NCT03926052
View directory record Official record
Conditions
Binge-Eating Disorder, Obesity
Interventions
Lisdexamfetamine Dimesylate, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

NCT01148979
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lisdexamfetamine Dimesylate (Vyvanse), Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 1, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

NCT00877487
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
55
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 1, 2026, 9:46 PM EDT